Moxifloxacin

AND CLINICAL USE ..................................................................................... 3 CONTRAINDICATIONS .......................................................................................................... 6 WARNINGS AND PRECAUTIONS .........................................................................................

6 ADVERSE REACTIONS ......................................................................................................... 15 DRUG INTERACTIONS .........................................................................................................

19 DOSAGE AND ADMINISTRATION ..................................................................................... 21 OVERDOSAGE .......................................................................................................................

22 ACTION AND CLINICAL PHARMACOLOGY .................................................................... 23 STORAGE AND STABILITY ................................................................................................. 31 SPECIAL HANDLING INSTRUCTIONS ...............................................................................

1). Consideration should be given to official guidance on the appropriate use of antibacterial agents.

7 ) To reduce the development of drug-resistant bacteria and maintain the effectiveness of moxifloxacin tablets and other antibacterial drugs. Moxifloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria.

3) ] . MDRSP isolates are isolates resistant to two or more of the following antibacterial drugs: penicillin (minimum inhibitory concentrations [MIC] ≥ 2 mcg/mL), 2nd generation cephalosporins (for example, cefuroxime), macrolides, tetracyclines, and trimethoprim/sulfamethoxazole.

4) ]. 5) ]. 6) ] . 5 Plague Moxifloxacin tablets are indicated in adult patients for the treatment of plague, including pneumonic and septicemic plague, due to susceptible isolates of Yersinia pestis and prophylaxis of plague in adult patients.

Efficacy studies of moxifloxacin could not be conducted in humans with plague for feasibility reasons. 7) ] . 1) ] . 14) ] and for some patients ABS is self-limiting, reserve moxifloxacin tablets for treatment of ABS in patients who have no alternative treatment options.